Imunon Reports Q3 2026 Financial Results and Clinical Trial Updates

Imunon, Inc. (IMNN) reported its third-quarter 2026 financial results, highlighting a net loss of $3.8 million ($0.64 per share). While research and development expenses saw a slight decrease to $1.8 million due to lower manufacturing costs, the company faces significant liquidity challenges. Management noted that completing the pivotal Phase III OVATION-3 clinical trial will require additional capital, and auditors have included a going concern warning in their financial reports. On the clinical front, the company reported positive data from its OVATION-2 study, showing a 14.7-month increase in median survival for patients treated with IMNN-001 compared to the control group. The OVATION-3 trial is progressing with enrollment productivity exceeding internal assumptions. Additionally, the sale of the ThermoDox asset provides potential milestone payments of up to $16.5 million and a 4.8% equity stake in partner VoxelDox.

8 articles from 3 sources · updated

Coverage